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ABSTRACT 
Objective: The aim of this study is to develop a gastroretentive microsphere of pregabalin using design of experiment (DoE) to decrease dosing 
frequency and increasing bioavailability.  
Methods: Pregabalin microsphere was prepared by W/O/O multiple emulsion method using a mixture of ethyl cellulose (EC) and polyvinyl 
pyrrolidone (PVP) as rate-controlling polymer. Mixed solvent system comprising of dichloromethane (DCM) and acetonitrile (ACN) and light liquid 
paraffin was chosen as primary and secondary oil phase respectively. Taguchi design was employed for factor screening and Box Behnken design 
was used for the optimisation of critical process parameters.  
Results: Taguchi design revealed that polymer: drug, DCM: ACN and PVP: EC is the critical factor for the preparation of microspheres. The 
optimized formulation was prepared using polymer: drug (4.95:1), DCM: ACN (53.76: 46.24) and PVP: EC (2:5) which showed mean particle size of 
203.34±4.82 µm, practical yield of 87.52±2.91 %, encapsulation efficiency of 96.43±3.14 %, floating ability up to 90.42±1.64 % and T60% of 
332.81±5.84. Drug release from microsphere followed Higuchi Kinetic model.  
Conclusion: In a nutshell, microspheres with excellent flowability and great encapsulation efficiency were successfully developed. These can be 
useful in improving patient compliance by reducing frequent dosing. 
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INTRODUCTION 
Oral drug delivery is the most commonly used route for drug 
administration because it has many advantages over other routes 
such as convenience, better patient compliance and flexibility in 
design of dosage form [1-3]. Over the past decades, oral controlled-
release (CR) formulation has evolved to prescription drug releases 
from dosage forms. But retaining the dosage form at the drug 
absorption site for a longer period of time is a challenge for 
conventional CR formulation, especially when the upper GIT is the 
absorption site.  
Gastro retentive drug delivery systems (GRDDS) overcome this 
limitation of conventional CR formulation and increase residence 
time in Upper GIT. Prolong retention in the upper GIT leads to 
maximum drug release in the “drug absorption window”. Thereby 
improving bioavailability [4]. Various approaches were used to 
develop GRDDS, including floating drug delivery, swellable drug 
delivery, bioadhesive drug delivery and high-density drug delivery 
[5, 6]. Studies have found floating drug delivery systems (FDDS) to 
be the most appropriate of these approaches [7-10]. Multiple unit 
FDDS have gained more attention than single unit systems FDDS due 
to their properties such as uniform distribution throughout GIT, 
more reproducible absorption, lesser variability in GI transit time 
and reduced risk of local drug irritation [11-14]. 
The emulsification solvent evaporation method is very common 
among the methods used in the preparation of microspheres. 
Commonly used O/W single emulsion method successfully 
encapsulates hydrophobic drugs, but the hydrophilic drug is not 
able to encapsulate in sufficient quantity with this method because 
the hydrophilic drug is rapidly diffused into the continuous phase. 
Therefore, double emulsion solvent evaporation method is being 
used for adequate encapsulation of hydrophilic drug. In several 
studies, W/O/W emulsification method has been used for the 
encapsulation of hydrophilic drugs, peptides, insulin and 
biopharmaceuticals [15, 16]. In this method an aqueous solution of 
drugs is emulsified in to polymer solution in organic solvents to 
prepare a W1/O emulsion. This W1/O emulsion is then emulsified 
in the external aqueous phase containing emulsifying agent to 
prepare W1/O/W2 emulsion. The organic volatile solvent 
evaporates and polymer forms a layer over the droplets. For high 
encapsulation efficiency, diffusion of the hydrophilic drug into the 
external phase is minimized by different approaches, such as by 
increasing viscosity of the external aqueous phase and using a 
stabilizer. Some studies have revealed that microspheres made 
from W/O/O emulsion method in which continuous phase is also 
oil, have higher encapsulation efficiency than W/O/W 
emulsification method [17, 18]. Because hydrophilic compounds 
cannot diffuse into the external phase since the oil is external 
processing medium. 
Pregabalin (PGB), a gabapentinoid drug, is widely used in diabetic 
neuropathy, post-herpetic neuralgia, fibromyalgia and partial-onset 
seizures [19]. Pregabalin has not been absorbed equally by GIT. It 
mainly absorbs from the upper GIT. Pregabalin has a half-life short, 
whereby the conventional pregabalin capsule available in the 
market is administered two to three times a day. Therefore to 
reduce the dosing frequency of pregabalin need a gastroretantive 
controlled release system [20].  
Systematic development of drug delivery systems using design of 
experiment (DoE) is an essential requirement of the current time 
[21]. In these techniques, the "best" formulation is chosen using 
lesser experiment, which saves time, effort and resources [22]. 
These techniques also helps in understanding the product and the 
process more thoroughly, leading to the development of a product 
with improved quality [23-25]. 
The goal of the present work, therefore, was to develop the gastro 
retentive microspheres of pregabalin using experiment designs for 
reducing dosing frequency. For this, W/O/O emulsion method was 
used and a combination of ethyl cellulose and poly vinyl pyrrolidone 
was chosen as the carrier. In the first phase the influencing factors 
were evaluated using factor screening study and later the optimized 
gastro retentive microsphere of pregabalin was selected with the 
help of response surface methodology. 
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MATERIALS AND METHODS 
Materials 
Pregabalin was received as a gift from M Sea Pharmaceuticals Pvt 
Ltd (Poanta Sahib; India). Ethylcellulose, cross link PVP and light 
liquid paraffin were procured from Himedia lab Ltd. (Mumbai; 
India). Dichloromethane (DCM), acetonitrile (ACN) and span 80 
were purchased from Fisher Scientific (Mumbai; India). All other 
chemicals used were of analytical grade.  
Preparation of microspheres by W/O/O multiple emulsion 
method 
EC and PVP were dissolved in a mixture of DCM and ACN. PGB was 
dissolved in water. Aqueous solution of PGB was added in to the 
polymer solution to prepare primary emulsion (W/O). This primary 
emulsion was further added slowly in to light liquid paraffin 
containing Span 80 and stirred at 1000 rpm for 2 hr at 25 °C. The 
prepared microspheres were collected through filtration and 
washed repeatedly with water. The microcapsules were dried in a 
vacuum oven for 10 h at 30 °C and stored in desiccators. 
Screening of influencing factors 
The Taguchi design was utilized for screening of factors [26, 3]. 
Seven factors were evaluated, i.e., polymer: drug, DCM: ACN, volume 
of aqueous phase(ml), the volume of continuous phase (ml), 
concentration of span 80 (%), rotation speed (rpm) and PVP: EC at 
their low and high levels (table 1). Particle size (µm), encapsulation 
efficiency (EE %) and time required for 60 % drug release (T60%, 
min) were the key CQAs studied thoroughly for selecting critical 
material attributes (CMAs) and critical process parameters (CPPs). 
Optimization of gastro retentive microsphere 
Systematic optimization of gastro retentive microsphere of pregabalin 
was done by Box-Behnken design (BBD) employing three critical 
factors, polymer: drug (X1); DCM: ACN (X2) and PVP: EC (X3), selected 
by factor screening study. Table 2 shows design matrix, composition of 
seventeen formulations in coded form and level of critical factors. A 
total seventeen gastroretantive microsphere formulations were 
prepared and evaluated for response variable such as particle size 
(µm), EE(%) and T60%(min). The second order quadratic models were 
applied to identify significant immediate interaction between studied 
critical factors. One-way analysis of variance (ANOVA) was employed 
to determine the significance of the model (P<0.05) and individual 
response. The residual plot and other parameters such as F-value, P-
value, regression coefficient (R2) and the lack of fit were used to 
determine the good fit of the model. Response surface analysis was 
performed with the help of 3D-plots for thorough understanding of the 
effect of each CMA and/or CPP on the CQAs. Finally, the optimized 
formulation was selected from the numerical optimization based on 
the desirability function and the design space was also determined by 
graphical optimization. 
Characterization of gastroretantive microspheres 
Practical yield of microsphere 
The collected dried microspheres were weighed and practical yield 





Where, Wm = Weight of microsphere, WE = Total weight of non-
volatile excipients 
Determination of particle size 
The particle size distribution of dried microsphere was determined 
employing a Malvern laser diffractometer (Mastersizer 2000 MS; 
Malvern Instruments, Worcestershire, UK) with a beam length of 
2.40 mm, range lens of 300 RF mm, at 14.4% obscuration. 
Determination of encapsulation efficiency 
The accurately weight microsphere equivalent to 150 mg of 
pregabalin were washed with distilled water to eliminate surface 
(unencapsulated) drug and then powdered in a mortar. The powder 
was transferred to a 50 ml volumetric flask containing 0.1N HCl and 
flask was shacked for 24 hr. After 24 hr solution was filtered and 
analysed employing ultraviolet spectroscopy at a λ max of 242.5 nm. 
The encapsulation efficiency (EE %) or drug loading was calculated 




 X 100 (2) 
Where, WA= Actual loading of drug, Wt = Theoretical loading of drug  
In vitro floating ability studies 
Floating ability of microsphere containing pregabalin was 
determined in the simulated gastric medium (0.1 N HCl). Accurately 
weighed 50 mg microspheres were dispersed over the surface of the 
dispersing medium (simulated gastric medium) kept in the USP type 
II dissolution test apparatus at 37 °C. The medium containing 
microspheres was agitated by paddles at 100 rpm for 12 h. After 12 
h, floating microspheres were collected, dried and weighed [7, 29]. 
Percentage of floating microsphere was determined by using the 
following formula [7]: 
Number of floating microsphere (%) =  
W12
W0
 X 100 (3) 
In vitro drug release study 
In vitro drug release study was performed in a USP dissolution 
apparatus (model–8000, Labindia Analytical Instruments Pvt. Ltd., 
Mumbai, INDIA) type I using 0.1 N HCl as the dissolution medium to 
imitate gastric condition at 37±0.5 °C and rotating at 100 rpm. The 
sample was withdrawn at predefined time intervals up to 12 h and 
replenished with an equal volume of fresh medium to maintain sink 
conditions. The sample was filtered through 0.45µ membrane filter 
and analysed using ultraviolet spectroscopy at a λ max of 242.5 nm 
(Shimadzu UV-1800 UV-VIS spectrophotometer, Japan) after 
suitable dilution [27, 30, 31].  
Drug release kinetics study 
The drug release mechanism from optimise gastro retentive 
microsphere was established by fitting the release data to different 
kinetic models such Zero-order, First-order, Higuchi, Hixson-Crowell 
and Korsmeyer-Peppas model. 
Scanning electron microscopy  
Morphology of the optimize gastroretantive microsphere was 
determined using scanning electron microscopy (SEM) imaging 
analysis (JEOL, JSM-5200,Tokyo, Japan). The dried microsphere was 
kept on an aluminium holder and coated for 90s with gold in an argon 
atmosphere by Sputter Coater® JFC-1100 (JEOL, Tokyo, Japan) [29].  
RESULTS AND DISCUSSION 
Gastroretantive microsphere is a multiple unit drug delivery system 
and is the most efficient method of drug delivery as they are evenly 
distributed in the upper GIT resulting in a reproducible and efficient 
controlled drug release at the target site [11]. Multiple emulsion 
(W/O1/O2) evaporation diffusion method was used to prepare 
gastroretantive microspheres. In this method, internal aqueous 
phase and external oil phase separate with an oil phase. In this 
process an aqueous solution of PGB emulsified in a mixed solvent 
system (MSS) containing polymer (EC and PVP) to prepare primary 
emulsion (W/O1). This primary emulsion is then added to light liquid 
paraffin containing span 80 (4%) to prepare W/O1/O2 emulsion. The 
organic solvent was removed from the W/O1/O2 emulsion by 
evaporation and extraction. The prepared microspheres were 
washed with n-hexane to remove light liquid paraffin and n-hexane 
also acted as solidifying agent for microspheres. 
Because of the continuous phase oil, it is necessary that the solvent 
in which the polymer dissolves is immiscible with oil. All organic 
solvents such as alcohol, acetone, dimethyl sulfoxide, 
tetrahydrofuran are oil-immiscible and do not forms emulsion with 
oil. Only acetonitrile is a unique organic solvent that is polar, water-
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miscible and oil-immiscible. But the formation of the primary 
emulsion cannot be ensured due to water-miscibility of ACN, as the 
aqueous drug solution is added to the polymer solution the polymer 
will precipitate. Therefore a MSS was used for polymer solution in 
which DCM, a non-polar solvent, was mixed with ACN. Due to the oil 
miscibility of DCM, solvent removal also occurs by extraction in the 
continuous phase. After mixing the primary emulsion in the 
continuous phase, DCM undergoes rapid extraction in the oil phase 
and the polymer solution becomes viscous. This prevents migration 
of aqueous drug solution thereby increasing encapsulation efficiency 
[17].  
Screening of influencing factors 
Firstly, the screening of variables with high influence on CQAs was 
performed employing Taguchi design. Table 1 shows low and high 
value of studied factors. Pareto charts were used for quantitatively 
recognizing the influence of each studied factors on the selected 
CQAs for screening. The objective of the pareto chart is to screen the 
most influential factor(s) among a typical large set of factor variables 
[32]. Based on Pareto chart (fig. 1), polymer: drug, DCM: ACN and 
PVP: EC showed a distinctly significant effect on the CQAs, and 
therefore, were selected as the critical factors for optimization of 
gastro retentive microsphere. 
 
Table 1: Level of factors for factor screening study using taguchi 
design 
Factors Level 
Low (-1) High (+1) 
A: Polymer: drug 1:1 5:1 
B: DCM: ACN 30:70 70:30 
C: Vol. of aqueous phase 1.0 3.0 
D: Vol. of continuous phase  100 300 
E: Con. of span 80 0.5 2.0 
F: Rotation speed 500 1500 
G: PVP: EC 0:1 2:5 
CQAs 
Y1= Particle Size (µm) 
Y2= Encapsulation efficiency (%)  
Y3= Time for 60% drug (T60%) 
ACN= Acetonitrile; DCM=Dichloromethane 
 
 
Fig. 1: Pareto chart depicting influence of process parameters on CQAs of gastro retentive microspheres (a) particle size (Y1), (b) EE (Y2) 
and (c) T60% (Y3) 
 
Table 2: Box-behnken design (BBD) matrix displaying seventeen formulations with varying levels of factors and result showing impact on CQAs 
Code Run X1 X2 X3 Y1* (mean±SD) Y2* (mean±SD) Y3* (mean±SD) 
MS1 1 0 -1 1 123.98±2.23 88.81±1.39 328±5.62 
MS2 2 0 -1 -1 93.56±1.83 78.16±1.63 433±3.26 
MS3 3 0 1 1 215.32±2.93 87.49±1.92 317±2.43 
MS4 4 -1 1 0 170.34±1.38 72.09±2.65 332±4.61 
MS5 5 -1 -1 0 95.67±3.82 73.38±1.35 342±3.24 
MS6 6 0 1 -1 182.88±1.57 77.92±1.79 436±5.73 
MS7 7 1 0 1 187.40±3.82 96.43±1.83 340±1.53 
MS8 8 0 0 0 150.83±1.58 83.48±1.62 365±2.83 
MS9 9 0 0 0 145.63±2.72 82.46±1.02 370±2.46 
MS10 10 1 0 -1 132.43±1.96 85.21±1.11 447±3.09 
MS11 11 -1 0 -1 126.53±0.93 68.85±1.86 399±4.32 
MS12 12 0 0 0 148.92±2.06 82.67±2.19 376±1.09 
MS13 13 0 0 0 146.21±1.53 83.67±1.56 368±3.25 
MS14 14 1 -1 0 119.45±2.42 90.32±1.21 388±2.46 
MS15 15 1 1 0 222.51±1.28 91.43±1.10 392±4.05 
MS16 16 -1 0 1 136.17±1.62 78.62±2.17 282±3.28 
MS17 17 0 0 0 142.61±2.24 83.27±1.63 373±4.82 
Factors -1 0 +1 
X1 = Polymer: drug 1:1 3:1 5:1 
X2 = DCM: ACN 30:70 50:50 70:30 
X3 = PVP: EC 0:1 1:5 2:5 
*Mean obtained from triplicate experiment (n=3), Y1= Mean particle size (µm)±SD; Y2 = Encapsulation efficiency (EE %); Y3=Time required to 60 % 
drug release (T60%, h); ACN= Acetonitrile; DCM=Dichloromethane 
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Table 3: Summary of ANOVA and other statistical parameters for the CQAs of gastroretantive microspheres of pregabalin 
Source SS Df MSS F P value Adj R2 Pred R2 Aedq preci 
Response Y1 (Particle size) 
Model 21215.17 9 2357.24 192.47 <0.0001 0.9908 0.9627 47.248 
Residual 85.73 7 12.25 - - - - - 
Lack of fit 45.73 3 15.24 1.52 0.3378 - - - 
Pure error 40.00 4 10 - - - - - 
Cor total 21300.90 16  - - - - - 
Response Y2 (Encapsulation efficiency) 
Model 840.54 9 93.39 333.40 <0.0001 0.9947 0.9815 68.768 
Residual 1.96 7 0.28 - - - - - 
Lack of fit 0.87 3 0.29 1.06 0.4588 - - - 
Pure error 1.09 4 0.27 - - - - - 
Cor total 842.50 16 - - - - - - 
Response Y3 ((T60%) 
Model 31348.06 9 3483.12 330.83 <0.0001 0.9946 0.9961 66.302 
Residual 73.70 7 10.53 - - - - - 
Lack of fit 0.50 3 0.17 9.10x10-3 0.9986 - - - 
Pure error 73.20 4 18.30 - - - - - 
Cor total 31421.76 16 - - - - - - 
 
 
Fig. 2: Different residual plots depicting goodness of fit of model for (a) particle size (Y 1), (b) EE (Y2) and (c) T60% (Y3) 
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Table 4: Coefficient and p-value of terms for the CQAs of gastro retentive microspheres of pregabalin 
Factor Response Y1 Response Y2 Response Y3 
Coefficient P value Coefficient P value Coefficient P value 
X1 16.64 <0.0001 8.81 <0.0001 26.50 <0.0001 
X2 44.80 <0.0001 -0.22 0.2832 -1.75 0.1710 
X3 15.93 <0.0001 5.15 <0.0001 -56.00 <0.0001 
X1X2 7.10 0.0048 0.60 0.0577 3.50 0.0679 
X1X3 11.33 0.0003 0.36 0.2131 2.50 0.1672 
X2X3 0.50 0.7812 -0.27 0.3416 -3.50 0.0679 
X12 -1.57 0.3865 -1.06 0.0045 -9.20 0.0007 
X22 6.73 0.0056 -0.24 0.3761 2.30 0.1891 
X32 0.37 0.8355 0.23 0.4046 5.80 0.0080 
Term indicated with Bold were insignificant (p>0.05) 
 
The mean particle size for all formulations was in the range 
93.56±1.83-222.51±1.28 µm. The residual plot (fig. 2a) for particle 
size depicted most of the coloured points representing values of 
particle size were situated around the normal probability line, which 
suggested that the observed value and predicted value of mean 
particle size were well fitted. The reduced polynomial equation for 
mean particle size in coded value was given below 
Y1 = +146.30 + 16.64 X1 + 44.80X2 + 15.93X3 + 7.10X1X2
+ 11.33X1X3 + 6.66X2
2 (4)  
The sign of coefficient (table 4) revealed that X1, X2 and X3 have a 
positive effect on the mean particle size. Similarly, interaction 
terms X1X2 and X1X3 have a positive effect on mean particle size. 
Quadratic terms X22 were favorable for increasing particle size. 
The 3-D response surface graph (fig. 3a) shows the effect of critical 
factors on particle size. The value of the coefficient revealed that 
the proportion of DCM has the highest effect over the particle size. 
The particle size increased as proportion of DCM increased. It has 
been noted that after the DCM is extracted off. The viscosity of the 
solution decreases [18]. Viswanathan et al. also reported that the 
size of the particle increased as proportion of DCM increased 
because the viscosity of a polymer solution increased as soon as 
DCM was extracted off [17]. The particle size increase with an 
increase in the proportion of polymer and PVP. This may be due to 
increased viscosity of solution which results in decreased shearing 
efficiency [33, 34].  
 
 
Fig. 3: 3D response surface plot depicting influence of critical parameters on CQAs of gastroretantive microspheres (a) particle size (Y1), 
(b) EE (Y2) and (c) T60% (Y3) 
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The EE (%) is an indicator of loading efficiency of drug and most 
important parameter for the development of microspheres. The EE (%) 
of various microspheres was ranged from 68.85±1.86 %-96.43±1.83 %. 
The residual plot of EE (fig. 2b) demonstrated goodness of fit of model. 
The p-value<0.05 of drug: polymer and PVP: EC indicated significant 
effect of on the EE, while DCM: ACN did not have a significant effect (p-
value<0.05) on EE (table 4). The effect of critical factors on EE is 
presented by reduced polynomial equation. 
Y2 = +83.10 + 8.81X1 − 0.22X2 + 5.15X3 + 0.60X1X2 − 0.11X1
2  (5) 
The sign of coefficient displayed that ratio of polymer and ratio of 
PVP has a positive effect on EE. The influence of critical variables on 
EE is depicted by response surface plot (fig. 3b). The ratio of 
polymer has the highest effect on EE followed by the ratio of PVP. 
The EE increased with increase in the ratio of polymer and ratio of 
PVP indicating an improvement in the loading efficiency of the drug.  
The T60% of all formulation varied from 282±3.28-447±3.09 min. 
Residual plot for goodness of model fit for T60% is shown in fig. 2c. It 
was observed that T60% was significantly (P<0.05) affected by the PVP: 
EC and polymer: drug (table 4). The effect of critical factors on T60% 
was presented as the reduced quadratic model equation as below. 
Y3 = +371.37 + 26.50X1 − 56.00X3 − 9.08X1
2 + 5.92X3
2 (6) 
Ratio of polymer had a positive effect whereas the ratio of PVP had a 
negative effect on T60%. This is illustrated in the contour plot (fig. 3c). 
From the plot it is revealed that the T60% increases with increase in 
the ratio of polymer and decrease in the ratio of PVP. It is noted that 
Increasing the amount of polymer in the matrix increases the diffusion 
path length thereby decreasing drug release [35]. EC is considered as a 
sustained release polymer due to low water solubility and low 
permeability and its effect on drug release from macrosphere was 
influenced by the inclusion of PVP in the matrix. PVP is a water-soluble 
polymer that can form a passage in the matrix when exposed to the 
dissolution medium and helps in the diffusion out of the drug. 
Therefore, the release of PVP ratio increases drug release. 
Selection of optimum formulation  
The CQAs acceptance value was set within a desired range to select 
optimum microsphere formulation and to create a design space for 
formulation and process parameters. The value of adequate 
precision greater than 4 revealed that applied model can employ to 
navigate design space [36] (table 3). The mean particle size was set 
to ≤ 200 µm, EE was set to maximize whereas T60% was set to ≥ 330 
min. Fig. 4 depicts an overlay plot comprising of two regions, the 
yellow region referring to the optimal region and the gray area 
where the response was not in the acceptance criterion [37]. 
To select optimum formulation, numerical optimization approach 
was employed and setting for optimum microsphere formulation is 
shown in table 5. Lower value of biases and relative biases indicated 
close agreement with small differences between the observed and 
targeted value of responses. 
 
 
Fig. 4: Design space and optimum setting for optimisation of gastroretantive microspheres 
 
Table 5: Level of parameters, predicate value and experimental result for optimise formulation 






X2 = 53.76: 46.24 
X3 = 2:5 
Y1 (µ) 198.98  203.45  4.47 2.24 0.959 
Y2 (%) 96.43  94.32 2.11 2.19 
Y3 (min) 339.46 332.81 6.65 1.96 
 
Characterization of the optimum gastroretentive microspheres 
Practical yield, entrapment efficiency and floating ability  
The practical yield and entrapment efficiency of the optimum gastro 
retentive microsphere were found 87.52±2.91 %, and 96.43±3.14 % 
respectively. The optimum gastroretantive microsphere showed 
excellent floating ability up to 90.42±1.64 %. 
Particle size 
The mean particle size and polydispersibility index (PDI) of 
optimum gastroretentive microsphere were found 203.34±4.82 µm 
and 0.65 respectively. 
Scanning electron microscopy  
The SEM photograph of the optimum gastroretentive microsphere is 
shown in fig. 5. The SEM photograph revealed that the prepared 
microspheres were almost spherical in shape and had a rough surface. 
In vitro dissolution and drug release kinetic study 
Dissolution study was performed in 0.1N Hcl for 12 h. In vitro drug 
release profiles of pregabalin from optimum gastroretentive 
microsphere has been presented in fig. 6. Table 6 shows the results 
of fitting of the drug release data for pregablin from the microsphere 
into various kinetic models. The result shows that pregabalin release 
found to be best fitted in the Higuchi kinetic model (R2= 0.9891) and 
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diffusional release exponent (n) of Korsmeyer Peppas model was 
found 0.7243 (<0.5) indicating grossly non fickian diffusion [38]. 
 
 
Fig. 5: SEM photograph of optimise microsphere 
 
Fig. 6: In vitro drug release of PGB from optimise microsphere
 
 
Fig. 7: Different model of drug release kinetic for optimise microsphere 
 
Table 6: Drug release kinetic analysis for optimized microsphere 
Zero order Higuchi kinetic First order Hixson crowel Korsmeyer peppas 
R2 Ko R2 Kh R2 K1 R2 Khc R2 n 
0.9364 0.1271 0.9891 3.804 0.9874 0.0034 0.962 0.0008 0.973 0.7243 
 
CONCLUSION 
In the present study, gastroretantive microsphere of pregabalin was 
successfully developed using W/O/O multiple emulsion method. The 
result pronounces that optimise microsphere exhibited great 
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